Jing-Jing Zhang

Jing-Jing Zhang

Auto-generated profile, based on publicly available information

Jing-Jing Zhang

Internal Medicine-Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, 233030, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2025 in iLIVER
Verified
Journal Article
Open access
JZJingjing Zhang
Jingjing Zhang
SFSong Feng
Song Feng
JXJian Xue
Jian Xue
CZChao Zhou
Chao Zhou
SFShuangnan Fu
Shuangnan Fu
NZNing Zhang
Ning Zhang
Metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with coronary artery disease (CAD), but existing risk assessment tools lack precision and scalability. We developed an AI-driven multimodal framework integrating traditional Chinese medicine (TCM) tongue-based diagnosis with clinical biomarkers to stratify CAD risk in MAFLD. In this cross-sectional study with prospective data collection, which comprised 1073 MAFLD patients stratified by CAD status (MAFLD without CAD, n = 942; MAFLD with CAD, n = 131), baseline characteristics were compared using chi-square tests for categorical variables and Mann-Whitney U tests for continuous variables, with p < 0.05 considered significant. We developed two distinct deep learning models: Model-1 (non-invasive) using ResNet18 combined tongue image features with demographic and comorbidity data, and Model-2 (comprehensive) incorporated blood biomarkers alongside the features used in Model-1. Multimodal feature fusion was achieved through a dedicated cross-attention network. Model performance was rigorously evaluated using 10-fold cross-validation, with area under the curve (AUC), sensitivity, and specificity as primary metrics. Focal loss was employed to address class imbalance. The coexistence of CAD was associated with significantly higher rates of hypertension, diabetes, and familial cardiovascular history in patients with MAFLD (p < 0.001), along with distinct metabolic profiles: elevated systemic inflammation (neutrophil-lymphocyte ratio), advanced fibrosis (FIB-4), elevated fasting glucose levels, and attenuated hepatic inflammation (ALT and AST). Model-1 achieved an AUC of 0.858 (sensitivity 0.778, specificity 0.908), while Model-2 demonstrated superior discrimination (AUC 0.933), particularly in tertiary care. Our AI-driven dual-model framework addresses the critical unmet need for CAD identification in MAFLD patients, providing a community-scalable screening tool (Model-1) and a precision clinical assessment model (Model-2), while offering empirical support for TCM tongue diagnosis. Pending external validation to confirm its generalizability, this approach may serve as a cost-efficient non-invasive screening strategy for this high-risk population.

21 November 2018 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
XHXiao Han
Xiao Han
JZJing-Jing Zhang
Jing-Jing Zhang
ZHZheng-Quan Han
Zheng-Quan Han
HZHai-Bin Zhang
Hai-Bin Zhang
ZWZi-An Wang
Zi-An Wang
The original version of this Article neglected to indicate that the study was supported by Anhui Natural Science Foundation Project (1608085MH201). This has now been corrected in both the PDF and HTML versions of the Article.